Zivo Bioscience, Inc. (ZIVO) Stock Price & Analysis

Zivo Bioscience, Inc. (ZIVO) rose 0.00% to USD 5 as of July 25, 2026 at 09:19 UTC, according to Nexqual real-time market data.

ZIVO last closed at USD 5; the session ranged USD 3.99–4.8 on volume of 4,979 shares. Market capitalization is $20.76M, with a 52-week range of USD 1.11–19.65 (OID). Source: Nexqual, July 25, 2026 at 09:19 UTC.

Key Statistics (as of July 25, 2026 at 09:19 UTC)

Technical Analysis (ZIVO)

Nexqual's technical model rates ZIVO "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 09:19 UTC.

Analyst Ratings (ZIVO)

Wall Street analysts rate ZIVO "None", per Nexqual as of July 25, 2026 at 09:19 UTC.

Earnings (ZIVO)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 09:19 UTC.

Financials & Fundamentals (ZIVO)

Source: Nexqual, July 25, 2026 at 09:19 UTC.

Financial Health Score (ZIVO)

Nexqual rates Zivo Bioscience, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:19 UTC.

Ownership (ZIVO)

Source: Nexqual, July 25, 2026 at 09:19 UTC.

Leadership (ZIVO)

Zivo Bioscience, Inc. is led by John Bernard Payne (age 77), President, CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 09:19 UTC.

Major Backers & Investors (ZIVO)

Notable institutional backers of Zivo Bioscience, Inc. include Corecap Advisors, LLC, according to Nexqual as of July 25, 2026 at 09:19 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 09:19 UTC.

From Zivo Bioscience, Inc.'s Latest SEC 10-K Filing (filed 2025-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• Overall, our efforts have been centered around two potential value-creating initiatives; the first being the identification of bioactive extracts or novel bioactive molecules from our proprietary algal culture to treat various diseases, and second, the utilization of our proprietary algal culture in its whole form as a food product to leverage its nutritional value.
• The dry, powdered form contains over 50% protein, is an excellent source of other essential vitamins and nutrients and has little odor and a mild taste compared with other algae products. When we conducted a review of our nutrition business, we were very satisfied with the nature of the product; however, we identified gaps in customer acquisition and in scale-up technology preventing us from growing our proprietary algae in quantities to sufficiently meet the potential demand.
• These results were not statistically different from the market-leading commercial ionophore.   ZIVO's approach for developing our coccidiosis product candidate as feed additives enables us to generate products that boost the immune response and reduce the effects of disease, while maintaining a single regulatory relationship, which is with the U.S.

Partnerships

• We have, therefore, focused our nutrition strategy on developing a cost effective, commercial-scale growing technology.      In 2021, we initiated a long-term collaboration, commencing a development agreement with Grupo Alimenta, a well-established family-run Peruvian agricultural conglomerate.
• Plans are to complete build-out at Alimenta Algae to reach full capacity in 2027, with capability to produce roughly 100,000 kg per year.   A significant milestone in this partnership is the transition from the development agreement to a commercial agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:19 UTC. This page is informational and not investment advice.